Abstract
Background: In liver cirrhosis nitric oxide (NO) signaling, including function of its receptor soluble guanylyl cyclase (sGC), is distorted. The sGC stimulator riociguat (RIO) is used as treatment for pulmonary hypertension and it has been shown that RIO acts antifibrotic. We thus aimed to investigate effects of RIO on experimental liver cirrhosis and portal hypertension.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
